OTCM
CYVNY
Market cap3mUSD
Sep 11, Last price
0.02USD
1D
0.00%
1Q
-8.37%
Name
Opthea Ltd
Chart & performance
P/E
—
P/S
157.32
EPS
—
Div yield, %
—
Shrs. gr., 5y
36.25%
Rev. gr., 5y
-29.73%
Revenues
25k
-79.95%
Net income
-164m
L-25.63%
CFO
-159m
L-1.12%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
Key people
Richard Chadwick
Head - Intellectual Property · since 2009
Mike Gerometta
Head of CMC Development
Ian Leitch
Director - Clinical Research · since 2011
Michael Tonroe
Chief Financial Officer, Company Secretary · since 2014
Chairman of the Board · since 2015
Michael Sistenich
Non-Executive Director · since 2015
Legal address
'Prime Company Compliance' Level 9
505 Little Collins Street
MELBOURNE, VIC 3000
AU
505 Little Collins Street
MELBOURNE, VIC 3000
AU
Headquarters
Level 9
505 Little Collins Street
MELBOURNE, VIC 3000
AU
505 Little Collins Street
MELBOURNE, VIC 3000
AU
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||